Beam CEO exercises options, sells 50K shares
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock.
Rhea-AI Filing Summary
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock. He exercised stock options for 50,000 shares of common stock at an exercise price of $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices of $22.3692 and $22.7634 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on May 16, 2025. Evans also received 90,000 restricted stock units under the Beam 2019 Equity Incentive Plan, vesting in four equal annual installments, and now holds 986,667 shares directly and 103,000 shares indirectly through a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 50,000 shares ($1.09M approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Evans John M.
Role
CEO
Sold
50,000 shs ($1.13M)
Approx. gross sale proceeds
$1.13M
Approx. exercise cost
$34K
Approx. pre-tax spread
$1.09M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $0.67 | $17K |
| Sale | Common Stock | 25,000 | $22.7634 | $569K |
| Grant/Award | Common Stock | 90,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $0.67 | $17K |
| Sale | Common Stock | 25,000 | $22.3692 | $559K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,672 contracts (Direct);
Common Stock — 1,076,667 shares (Direct);
Common Stock — 103,000 shares (Indirect, By John M. Evans, III 2018 Irrevocable Trust)
Footnotes (5)
- F1. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.
- F5. On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
Key Figures
Options exercised: 50,000 shares at $0.67/share
Shares sold: 50,000 shares
Sale price range (set 1): $22.03–$22.70 per share
+4 more
7 metrics
Options exercised
50,000 shares at $0.67/share
Stock option exercises in March 2026
Shares sold
50,000 shares
Open-market sales at $22.3692 and $22.7634 per share
Sale price range (set 1)
$22.03–$22.70 per share
Weighted average price footnote for one sale
Sale price range (set 2)
$22.34–$23.21 per share
Weighted average price footnote for second sale
RSUs granted
90,000 units
Restricted stock units vesting over four years
Direct holdings after trades
986,667 shares
Common stock directly owned post-transaction
Indirect trust holdings
103,000 shares
Held by John M. Evans, III 2018 Irrevocable Trust
Key Terms
Rule 10b5-1 trading plan, restricted stock units ("RSUs"), weighted average price, Equity Incentive Plan, +2 more
6 terms
Rule 10b5-1 trading plan financial
"These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Equity Incentive Plan financial
"RSUs granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
development milestone financial
"vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications."
base editing applications technical
"achievement of a certain development milestone related to base editing applications."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Beam Therapeutics (BEAM) CEO John M. Evans report?
John M. Evans exercised options for 50,000 Beam Therapeutics shares at $0.67 per share and sold 50,000 shares in open-market trades. He also received 90,000 restricted stock units that vest over four years, increasing his long-term equity-based compensation.
How many Beam Therapeutics (BEAM) restricted stock units did the CEO receive?
Evans received 90,000 restricted stock units under the BEAM 2019 Equity Incentive Plan. Each RSU represents one common share, vesting in four substantially equal installments on each of the first four anniversaries of the grant date, contingent on continued service with Beam Therapeutics.
What are the Beam Therapeutics (BEAM) CEO’s holdings after these transactions?
After the reported transactions, Evans directly holds 986,667 shares of Beam Therapeutics common stock. The filing also shows an indirect holding of 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, reflecting additional exposure via a related trust structure.
What option exercise terms applied to the Beam Therapeutics (BEAM) CEO’s Form 4?
Evans exercised stock options covering 50,000 shares of Beam common stock at an exercise price of $0.67 per share. These options were originally granted in 2018 and vested upon achievement of a specified development milestone related to base editing applications, as determined in 2024.
AI-generated analysis. How Rhea-AI works. Not financial advice.
